Hypertension and Heart Failure: From Pathophysiology to Treatment
International Journal of Molecular Sciences · 17.06.2024 · 25 (12) · 6661
DOI: 10.3390/ijms25126661 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.06.2024. Verfasst von Giovanna Gallo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Molecular Medicine Department, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University of Rome, 00189 Rome, Italy. Hauptthemen laut MEDLINE: Heart Failure, Hypertension, Antihypertensive Agents. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Hypertension represents one of the primary and most common risk factors leading to the development of heart failure (HF) across the entire spectrum of left ventricular ejection fraction. A large body of evidence has demonstrated that adequate blood pressure (BP) control can reduce cardiovascular events, including the development of HF. Although the pathophysiological and epidemiological role of hypertension in the development of HF is well and largely known, some critical issues still deserve to be clarified, including BP targets, particularly in HF patients. Indeed, the management of hypertension in HF relies on the extrapolation of findings from high-risk hypertensive patients in the general population and not from specifically designed studies in HF populations. In patients with hypertension and HF with reduced ejection fraction (HFrEF), it is recommended to combine drugs with documented outcome benefits and BP-lowering effects. In patients with HF with preserved EF (HFpEF), a therapeutic strategy with all major antihypertensive drug classes is recommended. Besides commonly used antihypertensive drugs, different evidence suggests that other drugs recommended in HF for the beneficial effect on cardiovascular outcomes exert advantageous blood pressure-lowering actions. In this regard, type 2 sodium glucose transporter inhibitors (SGLT2i) have been shown to induce BP-lowering actions that favorably affect cardiac afterload, ventricular arterial coupling, cardiac efficiency, and cardiac reverse remodeling. More recently, it has been demonstrated that finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces new-onset HF and improves other HF outcomes in patients with chronic kidney disease and type 2 diabetes, irrespective of a history of HF. Other proposed agents, such as endothelin receptor antagonists, have provided contrasting results in the management of hypertension and HF. A novel, promising strategy could be represented by small interfering RNA, whose actions are under investigation in ongoing clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical and Molecular Medicine Department, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University of Rome, 00189 Rome, Italy.
ORCID-Profile: Giovanna Gallo, Carmine Savoia
Zitieren
APA
Gallo, G., & Savoia, C. (2024). Hypertension and Heart Failure: From Pathophysiology to Treatment. International Journal of Molecular Sciences, 25(12), 6661. https://doi.org/10.3390/ijms25126661
Vancouver
Gallo G, Savoia C. Hypertension and Heart Failure: From Pathophysiology to Treatment. International Journal of Molecular Sciences. 2024;25(12):6661. doi:10.3390/ijms25126661
BibTeX
@article{Gallo2024,
author = {Gallo, Giovanna and Savoia, Carmine},
title = {Hypertension and Heart Failure: From Pathophysiology to Treatment},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {12},
pages = {6661},
doi = {10.3390/ijms25126661}
}
EUVIMED